Brain stimulation

Publication Analyzes Clinical Efficacy of Deep TMS™ in Treating Different Brain Regions Associated with Major Depressive Disorder

Retrieved on: 
Tuesday, January 31, 2023
TASE, Mental health, Journal of Clinical Investigation, Journal, Insight, Brain stimulation, Psychiatry, H1, Comparison, EEG, TMS, Ben-Gurion University of the Negev, Depression, Patient, Prefrontal cortex, Anxiety, JCI, Brainsway, Deep, Research, Pharmaceutical industry, Medical imaging

The primary endpoint of the study – non-inferiority of the H7 Coil in reducing depressive scores when compared to the H1 Coil – was successfully demonstrated among the overall patient population.

Key Points: 
  • The primary endpoint of the study – non-inferiority of the H7 Coil in reducing depressive scores when compared to the H1 Coil – was successfully demonstrated among the overall patient population.
  • This study served as the basis for BrainsWay’s August 2022 H7 Coil FDA clearance for depression.
  • This retrospective analysis was referred to in the publication as the “Clinical Differential Predictor” for TMS H-Coils.
  • Once we apply the categorization technique employed in this study, the potential exists to increase depression response rates even further.

Feinstein Institutes Bioelectronic Medicine Researchers Target Specific Vagus Nerve Fibers for More Precise, Effective Stimulation

Retrieved on: 
Friday, November 4, 2022
Research, Surgery, Medical Devices, Clinical Trials, Health Technology, Cardiology, Biotechnology, Health, Science, Doctor of Philosophy, Medical research, Hertz, SPARC, Neuroscience, Research, Science, Map, Lupus, Multimedia, Human, Mouse, Brain stimulation, Brain, Heart rate, Feinstein Institute for Medical Research, National, Rheumatoid arthritis, Vagus nerve stimulation, Condition, Inflammation, Mental health, Anatomy, Vagus nerve, Genetics, CEO, Credit, VNS, Nerve, Reflex, Medicine, Cough, Northwell Health, Autoimmunity, Vocal cords, Diabetes, Disease, Biomedical engineering, NIH, Molecular medicine, Cancer, RATS, Medical device, Pharmaceutical industry, MD

A new paper published in Brain Stimulation showed that delivering high-frequency electrical stimulation activates specific sensory nerve fibers of the vagus nerve and could be the key to better targeting and treating inflammation and disease.

Key Points: 
  • A new paper published in Brain Stimulation showed that delivering high-frequency electrical stimulation activates specific sensory nerve fibers of the vagus nerve and could be the key to better targeting and treating inflammation and disease.
  • View the full release here: https://www.businesswire.com/news/home/20221104005611/en/
    Dr. Stavros Zanos recently led the study, which targets specific fibers in the vagus nerve for more precise electrical stimulation.
  • (Credit: Feinstein Institutes)
    The research study, led by Stavros Zanos, MD, PhD , associate professor at the Feinstein Institutes Institute of Bioelectronic Medicine , measured how vagus nerve stimulation (VNS) using kHz stimulation an electrical stimulus that is commonly used to block nerve conduction at over 1,000 pulses per second affects the activity of different types of vagal fibers.
  • Previous VNS therapies would stimulate the whole nerve bluntly, without targeting specific fibers, which could cause adverse effects and less effective therapy.

BrainsWay Announces Multiple Publications of New Real-World OCD Data for its Deep TMS™ System

Retrieved on: 
Wednesday, January 12, 2022
Income, U.S. Securities and Exchange Commission, Research, Patient, Tic disorder, Technology, News, Legislation, International Classification of Functioning, Disability and Health, Journal, Psychiatry, CBT, Private Securities Litigation Reform Act, COVID-19, Safety, Obsessive–compulsive disorder, Knowledge, NASDAQ, Â, GLOBE, World, Review, Health, Insurance, Brain stimulation, Market access, TMS, Uncertainty, Lists of diseases, Addiction, Obsessions, Journal of Psychiatric Research, Company, Compulsions, Quality of life, TASE, WHO, MD, Deep, World Health Organization, Annual report, OCD, Transcranial magnetic stimulation, FDA, Genta (company), Failure, Brainsway, Awareness, Pharmaceutical industry, Medicare

While prior research has demonstrated the safety and efficacy of Deep TMS in treating OCD, a recent study published in Brain Stimulation now shows the durability of Deep TMS and the significant reduction in functional disability.

Key Points: 
  • While prior research has demonstrated the safety and efficacy of Deep TMS in treating OCD, a recent study published in Brain Stimulation now shows the durability of Deep TMS and the significant reduction in functional disability.
  • Additionally, positive data published in the Journal of Psychiatric Research support the cost-effectiveness of Deep TMS relative to other available treatment options for OCD.
  • Durability was defined as the elapsed time from the end of the Deep TMS treatment course until there was a change in ongoing treatment.
  • The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives.

BrainsWay Announces Data Published in World Psychiatry on Deep Transcranial Magnetic Stimulation (Deep TMS™) for Smoking Addiction

Retrieved on: 
Thursday, September 30, 2021
Addiction, Food, News, Insurance, Addiction medicine, Review, Smokeless tobacco, Failure, Bupropion, Â, World Psychiatric Association, Nicotine, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Annual report, Health, Private Securities Litigation Reform Act, NASDAQ, Brainsway, CMR, FDA, U.S. Securities and Exchange Commission, Transcranial magnetic stimulation, Varenicline, Death, Headache, Tobacco, Deep, World Psychiatry, TMS, Ben-Gurion University of the Negev, Addictive behavior, Head, Prefrontal cortex, Genta (company), Legislation, Company, Smoke, Knowledge, Lists of diseases, TASE, Brain stimulation, Awareness, COVID-19, Technology, Uncertainty, Psychiatry, Work, Safety, Smoking, Psychotherapy, Tic disorder, GLOBE, Pharmaceutical industry

BURLINGTON, Mass. and JERUSALEM, Sept. 30, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay'' or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced data published in World Psychiatry, the official publication of the World Psychiatric Association, from a pivotal, multicenter, placebo-controlled, double-blind clinical trial, supporting the use of Deep TMS™ as a safe and effective treatment for tobacco use disorder – one of the most common substance use disorders and leading cause of preventable death worldwide.

Key Points: 
  • With 15 sites enrolled in the CMR, BrainsWay has also transitioned to the limited rollout of systems to existing customers to support growing demand.
  • There is still much work to be done to explore the full utility of Deep TMS in the field of addiction.
  • The global economic burden of smoking is estimated to be $1.852 trillion every year: nearly 2% of the World GDP.
  • The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives.

New Data Highlights NeuroStar® Advanced Therapy for Mental Health Safety Over H-Coil TMS

Retrieved on: 
Tuesday, September 21, 2021
Interim, Clinical, NASDAQ, Depression, FDA, Transcranial magnetic stimulation, Patient, Contact, TMS, MD, Board, Mental health, Marketing, Brain stimulation, Lists of diseases, Advanced Therapy Medicinal Product, Risk, Technology, Research, R&D, VP, Brain, R, Neuroscience, Seizure, Quality of life, STIM, Industry, GLOBE, Pharmaceutical industry

One-hundred thirty-four surveys were returned and nine were excluded due to data inconsistencies, leaving a total of 125 surveys to evaluate which included 586,656 TMS treatment sessions.

Key Points: 
  • One-hundred thirty-four surveys were returned and nine were excluded due to data inconsistencies, leaving a total of 125 surveys to evaluate which included 586,656 TMS treatment sessions.
  • The resulting data provide the largest real-world sample size estimation of TMS seizure risk across device manufacturers.
  • An FDA-cleared, non-drug, noninvasive treatment for people with depression, Neuronetics NeuroStar Advanced Therapy system is todays leading transcranial magnetic stimulation (TMS) treatment for major depressive disorder in adults with over four million treatments delivered.
  • NeuroStar is widely researched and backed by the largest clinical data set of any TMS system for depression, including the worlds largest depression Outcomes Registry.

Aleva Neurotherapeutics Recruits First Patient into its PMCF Study with its directSTIM™ Directional Deep Brain Stimulation System

Retrieved on: 
Thursday, June 17, 2021
Medicine, Branches of biology, Clinical medicine, Neurotechnology, Electrotherapy, Medical devices, Neurosurgical procedures, Deep brain stimulation, Tourette syndrome, Essential tremor, Brain stimulation, Dystonia

The revenue-generating study aims to demonstrate improved outcomes with the technology of Alevas directSTIMTM Directional Deep Brain Stimulation system in the EU for Parkinsons Disease and Essential Tremor.

Key Points: 
  • The revenue-generating study aims to demonstrate improved outcomes with the technology of Alevas directSTIMTM Directional Deep Brain Stimulation system in the EU for Parkinsons Disease and Essential Tremor.
  • As one of the originators of Directional Deep Brain Stimulation, Aleva has done a substantial amount to study this modality and its benefit to patients.
  • Our Deep Brain Stimulation System incorporates several technologies that will provide better outcomes for Parkinsons patients," said Andr Mercanzini PhD, CEO of Aleva Neurotherapeutics.
  • Deep brain stimulation (DBS) is approved worldwide for the treatment of Parkinsons disease (PD), essential tremor, dystonia, obsessive-compulsive disorder (OCD), and epilepsy.

Nexstim granted authorization for commercial distribution of NBS system in Australia

Retrieved on: 
Tuesday, May 18, 2021
Branches of biology, Neurotechnology, Neuroscience, Electrotherapy, Neurophysiology, Medical devices, Neuropsychology, Transcranial magnetic stimulation, Brain stimulation

b'The medical device license allows the company to start marketing and selling NBS systems in Australia to be used for neurosurgical applications.\nNexstim\xe2\x80\x99s NBS System is the only FDA cleared system based on navigated Transcranial Magnetic Stimulation (nTMS) for non-invasive mapping of the speech and motor cortices of the brain.

Key Points: 
  • b'The medical device license allows the company to start marketing and selling NBS systems in Australia to be used for neurosurgical applications.\nNexstim\xe2\x80\x99s NBS System is the only FDA cleared system based on navigated Transcranial Magnetic Stimulation (nTMS) for non-invasive mapping of the speech and motor cortices of the brain.
  • In Europe, the NBT\xc2\xae system is CE marked for the treatment of major depression and chronic neuropathic pain.\nIn addition, Nexstim is commercializing its SmartFocus\xc2\xae based Navigated Brain Stimulation (NBS) system for diagnostic applications.
  • The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
  • Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.\n'

Neuroelectrics Raises $17.5M to Advance Clinical Trials for the Treatment of Epilepsy and Major Depressive Disorder with a New Platform for Treating Brain Dysfunction

Retrieved on: 
Tuesday, May 4, 2021
Mental health, Medical devices, Health, Other Health, Clinical trials, Biotechnology, Branches of biology, Neuroscience, Biology, Neurophysiology, Neurotechnology, Ana Maiques, Neuroelectrics, Neuromodulation, Brain stimulation

b'Neuroelectrics, a pioneer in brain stimulation technologies and therapies, has raised $17.5M in a Series A financing led by Morningside Ventures.

Key Points: 
  • b'Neuroelectrics, a pioneer in brain stimulation technologies and therapies, has raised $17.5M in a Series A financing led by Morningside Ventures.
  • Our goal is to offer a safe, non-invasive option that benefits those for whom effective treatments are unavailable,\xe2\x80\x9d said Ana Maiques, co-founder and CEO of Neuroelectrics.
  • The platform combines safe and proven neuromodulation capabilities with remote-controlled delivery and personalized treatment protocols to restore and maintain brain health.
  • Based in Cambridge, Massachusetts and Barcelona, Neuroelectrics has an expanding pipeline of computationally driven solutions for neurologic and psychiatric disease.

Using Rapid-Acting Brain Stimulation for Treatment-Resistant Depression - A Free Webinar from the Brain & Behavior Research Foundation

Retrieved on: 
Tuesday, May 4, 2021
Branches of biology, Medicine, Neuroscience, Neurotechnology, Electrotherapy, Medical devices, Neurophysiology, Neuropsychology, Brain & Behavior Research Foundation, Transcranial magnetic stimulation, Treatment-resistant depression, Brain stimulation

b'New York, May 04, 2021 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, \xe2\x80\x9cUsing Rapid-Acting Brain Stimulation for Treatment-Resistant Depression\xe2\x80\x9d on Tuesday, May 11, 2021, from 2pm to 3pm ET.

Key Points: 
  • b'New York, May 04, 2021 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, \xe2\x80\x9cUsing Rapid-Acting Brain Stimulation for Treatment-Resistant Depression\xe2\x80\x9d on Tuesday, May 11, 2021, from 2pm to 3pm ET.
  • Past research has demonstrated that a form of FDA-approved non-invasive brain stimulation called rTMS could be optimized to better treat depression as well as other psychiatric disorders.
  • Jeffrey Borenstein, M.D., President and CEO of the Brain & Behavior Research Foundation and Host and Executive Producer of the public television series \xe2\x80\x9cHealthy Minds,\xe2\x80\x9d will be the moderator.
  • Join by phone or on the web at bbrf.org/maywebinar.\nThis webinar is part of a series of free monthly \xe2\x80\x9cMeet the Scientist\xe2\x80\x9d webinars on the latest developments in psychiatry offered by the Brain & Behavior Research Foundation.

Medtronic Receives CE Mark Approval for SenSight™ Directional Lead System for DBS Therapy

Retrieved on: 
Monday, March 22, 2021
Health sciences, Medicine, Neurotechnology, Medical technology, Electrotherapy, Medical devices, Neurosurgical procedures, Deep brain stimulation, Tourette syndrome, Neurostimulation, DBS, Brain stimulation

DUBLIN, March 22, 2021 /PRNewswire/ --Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the CE (Conformit Europenne) Mark for the SenSight directional lead system for Deep Brain Stimulation (DBS) therapy as treatment of symptoms associated with movement disorders and epilepsy.

Key Points: 
  • DUBLIN, March 22, 2021 /PRNewswire/ --Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the CE (Conformit Europenne) Mark for the SenSight directional lead system for Deep Brain Stimulation (DBS) therapy as treatment of symptoms associated with movement disorders and epilepsy.
  • The SenSight directional DBS lead system works seamlessly with certain Medtronic neurostimulators, including the recently-approved PerceptPC neurostimulator.This system will enhance detection of local field potentials (LFPs) and offers directional stimulation to provide individualized and patient-specific data plus additional programming features to tailor therapy for patients.
  • "The challenge of DBS is to provide stimulation to a very small brain region only at times, when fluctuating symptoms require treatment.
  • "Our commitment to evolving DBS therapy is unwavering and we look forward to introducing additional advancements in 2021 and beyond."